Källén B, Rydhstroem H, Aberg A
Tornblad Institute, and the Department of Obstetrics and Gynecology, University of Lund, Sweden.
Obstet Gynecol. 1999 Mar;93(3):392-5.
To study possible teratogenic risks with the use of an inhaled glucocorticoid, budesonide, in early pregnancy.
Using the Swedish Medical Birth Registry, congenital malformations were studied in 2014 infants whose mothers had used inhaled budesonide for asthma in early pregnancy. The presence of congenital malformations was checked further with auxiliary registries.
No increase in the general rate of congenital malformations was observed: 3.8% (95% confidence interval [CI] 2.9, 4.6) of the infants had a congenital malformation diagnosed, which is similar to the population rate (3.5%). After exposure to budesonide, four infants were born with orofacial clefts; this also is similar to the expected number (3.3).
Even though a specific teratogenic effect of use of budesonide in early pregnancy cannot be ruled out, it is unlikely that a clinically significant teratogenic risk exists.
研究妊娠早期使用吸入性糖皮质激素布地奈德可能存在的致畸风险。
利用瑞典医学出生登记处的数据，对2014名母亲在妊娠早期因哮喘使用吸入性布地奈德的婴儿的先天性畸形进行了研究。通过辅助登记处进一步检查先天性畸形的情况。
未观察到先天性畸形总体发生率增加：3.8%（95%置信区间[CI]2.9，4.6）的婴儿被诊断患有先天性畸形，这与总体发生率（3.5%）相似。暴露于布地奈德后，有4名婴儿出生时患有口面部裂；这也与预期数量（3.3）相似。
尽管不能排除妊娠早期使用布地奈德存在特定致畸作用，但临床上显著的致畸风险不太可能存在。
